- Biora Therapeutics ( NASDAQ: BIOR ), a biotech focused on oral biotherapeutics, announced Friday that its common stock would start trading on a split-adjusted basis when the market opens on Jan. 03 following a 1-for-25 reverse stock split.
- After the reverse stock split, the number of shares of Biora’s ( BIOR ) common stock will drop to 164M from 350M.
- The reverse stock split authorized by the company’s Board of Directors comes with the approval of Biora ( BIOR ) shareholders, who gave their go-ahead at a special stockholder meeting on Dec. 19.
- The company has executed the reverse stock split to regain the Nasdaq compliance for minimum listing per share price requirement.
- Read: Seeking Alpha contributor Busted IPO Forum takes a deep dive on Biora’s ( BIOR ) transition from a genetic testing company to a developmental-stage drug company.
For further details see:
Biora Therapeutics announces 1-for-25 reverse stock split